Orexo AB
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Nikolaj Sørensen
- Full Time Employees
- 74
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- Virdings Allé 22 Uppsala UP Sweden 11148
- IPO Date
- Nov 9, 2005
- Website
- orexo.com
- Similar Companies
- Business
- Orexo AB (publ) (ORX.ST) is a Swedish specialty pharmaceutical company that develops and commercializes innovative pharmaceuticals and digital therapies primarily targeting opioid use disorder, addiction-related conditions, and other unmet medical needs using proprietary drug delivery technologies such as sublingual and nasal powder platforms. The company offers Zubsolv sublingual tablets for opioid dependence treatment; Abstral sublingual tablets for breakthrough cancer pain; Edluar sublingual tablets for short-term insomnia; and digital therapies including deprexis for depression, vorvida for alcohol use disorder, and modia for opioid use disorder; it also advances a pipeline featuring OX124 (iCIPRI) and OX125 as high-dose nasal naloxone and nalmefene rescue medications for opioid overdose, OX640 as a powder-based epinephrine nasal product for anaphylaxis, OX390 as an intranasal rescue medication for adulterated opioid overdoses, and OX-MPI for endometriosis in collaboration with Gesynta Pharma. Orexo operates through segments including US Pharma for commercial sales, Digital Therapeutics, and HQ/Pipeline for research, development, and out-licensing; it serves markets in the United States, European Union, United Kingdom, and internationally with a focus on patients, healthcare providers, and partners. Founded in 1994 and headquartered in Uppsala, Sweden, the company employs approximately 110 people and reported net sales of SEK 590 million in 2024. Recent developments include a September 2025 BARDA contract award of up to USD 50.9 million (initial USD 8 million) to Orexo US for OX390 development, conversion of future OX-MPI rights to SEK 19 million in Gesynta Pharma shares, preparation for Izipry (OX124) commercial launch as a nasal overdose rescue medication, ongoing partnering discussions and market research for OX640, a collaboration with Abera Bioscience on nasal powder vaccines using AmorphOX technology, and reaffirmation of 2025 positive EBITDA guidance amid Q3 revenue challenges.
Company News
Orexo reaches non-binding agreement in principle to settle investigation by US Department of Justice
Orexo reaches non-binding agreement in principle to settle investigation by US Department of Justice
Orexo AB (publ) (ORXOY) Q2 2026 Earnings Call Transcript
Orexo AB (publ) (ORXOY) Q1 2026 Earnings Call Transcript
Invitation & Agenda: Orexo R&D Day on March 24
Invitation & Agenda: Orexo R&D Day on March 24
Orexo changes the organizational structure and management team to increase focus on development of new products
Orexo AB (publ) (ORXOY) Q4 2025 Earnings Call Transcript
Orexo AB (publ) (ORXOY) Discusses Divestment of US Rights to Zubsolv and Transition Agreement with Dexcel Pharma Transcript
Orexo AB (publ) (ORXOY) Q3 2025 Earnings Call Transcript
Orexo's AmorphOX technology may pave the way for intranasal GLP-1 medication
Orexo to present clinical data for OX640 at the EAACI Congress
Orexo announces positive data for powder-based intranasal vaccine formulated with the AmorphOX technology
Orexo announces positive topline data from clinical study of OX640 in subjects with and without allergic rhinitis
Orexo enters into collaboration with Abera to develop nasal powder vaccines based on the AmorphOX technology
Orexo initiates new study of OX640 in participants with allergic rhinitis
Orexo´s Nomination Committee for the Annual General Meeting 2025
Orexo to participate in Pareto Securities´ 15th Annual Healthcare Conference 2024
Orexo shares new information on OX124, a high-dose naloxone rescue medication in development for opioid overdose
Orexo AB´s sustainability work ranked among top 5% by EcoVadis